Recent Quotes (30 days)

You have no recent quotes
chg | %

Revive Therapeutics Ltd  

(Public, CVE:RVV)   Watch this stock  
Find more results for RVV
-0.030 (-15.79%)
Oct 20 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.16 - 0.16
52 week 0.09 - 0.76
Open 0.16
Vol / Avg. 22,000.00/39,236.00
Mkt cap 8.02M
P/E     -
Div/yield     -
EPS -0.12
Shares 47.50M
Beta     -
Inst. own     -
Oct 19, 2016
Q4 2016 Revive Therapeutics Ltd Earnings Release (Estimated)

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -192.60% -101.32%
Return on average equity -408.90% -112.00%
CDP Score - -


5 Director Crt Suite 105
+1-905-6055535 (Phone)
+1-905-2483355 (Fax)

Website links


Revive Therapeutics Ltd. is a Canada-based clinical-stage company. The Company is focused on commercializing treatments for gout and orphan drug indications, such as cystinuria, Wilson disease and Rett syndrome. The Company's business model focuses on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace. The Company is focused on the development of its candidate, REV-002, which is bucillamine for treatment of gout. Other candidates in the Company's product pipeline include REV-001, which is tianeptine for treatment of opioid-induced respiratory depression in a perioperative setting; REV-003, which is tianeptine for treatment of Rett Syndrome; REV-004, which is bucillamine for the treatment of cystinuria, and REV-005, which is bucillamine for the treatment of Wilson disease.

Officers and directors

Craig Leon Chairman of the Board, Chief Executive Officer
Fabio Chianelli President, Director
Carmelo Marrelli Chief Financial Officer, Secretary
Robbie Grossman Director
Age: 40
Scott Johnson Director
Age: 36
Anton Konovalov Director
Age: 26
Reiza Rayman M.D. Director
Age: 51
Carlo Sansalone Director
Age: 35